US Patent

US8679533 — Pramipexole once-daily dosage form

Method of Use · Assigned to Pharmacia LLC · Expires 2029-09-08 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a once-daily dosage form of pramipexole dihydrochloride that releases the active ingredient in a controlled manner.

USPTO Abstract

An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-219 pramipexole-dihydrochloride
U-219 pramipexole-dihydrochloride
U-219 pramipexole-dihydrochloride
U-219 pramipexole-dihydrochloride
U-219 pramipexole-dihydrochloride
U-219 pramipexole-dihydrochloride
U-219 pramipexole-dihydrochloride

Patent Metadata

Patent number
US8679533
Jurisdiction
US
Classification
Method of Use
Expires
2029-09-08
Drug substance claim
No
Drug product claim
Yes
Assignee
Pharmacia LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.